Tango Therapeutics TNGX Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.
The official record: Tango Therapeutics’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's change in deferred revenue?
- Tango Therapeutics (TNGX) reported change in deferred revenue of $0 in Q4 2025.
- How has Tango Therapeutics's change in deferred revenue changed year-over-year?
- Tango Therapeutics's change in deferred revenue increased by 100.0% year-over-year, from -$4.12M to $0.
- What is the long-term trend for Tango Therapeutics's change in deferred revenue?
- Over 3 years (2022 to 2025), Tango Therapeutics's change in deferred revenue has grown at a 54.7% compound annual growth rate (CAGR), from -$16.86M to -$62.38M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.